Paradigm Biopharmaceuticals Ltd’s (ASX:PAR) Paul Rennie tells Proactive's Andrew Scott that additional data on patients who received Zilosul® under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS), brings the cumulative average WOMAC reduction in pain from baseline for the 89-patient cohort to 49.6%. Rennie says it's been encouraging to see a consistent clinically meaningful reduction in pain and improvement in joint function in osteoarthritis patients, who have failed to respond to other medications.
Paradigm Biopharma highlights 'remarkable consistency' in positive data from Zilosul® study
